# A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

> **NCT06079476** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 100 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Romosozumab

## Key facts

- **NCT ID:** NCT06079476
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-30
- **Primary completion:** 2025-10-18
- **Final completion:** 2025-10-18
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079476, "A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06079476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*